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Abstract
Importance—Despite antirestenotic efficacy of coronary drug-eluting stents (DES) compared
with bare metal stents (BMS), the relative risk of stent thrombosis and adverse cardiovascular
events is unclear. Although dual antiplatelet therapy (DAPT) beyond one year provides ischemic
event protection following DES, ischemic event risk is perceived to be less following BMS and
the appropriate duration of DAPT following BMS is unknown.

Author Manuscript

Address for Correspondence: Laura Mauri, MD, MSc, Division of Cardiovascular Medicine, Department of Medicine, Brigham and
Women's Hospital, 75 Francis Street; Boston, MA 02115, lmauri1@partners.org.
Author Contributions: Drs. Kereiakes and Mauri had full access to all the data in the study and take responsibility for the integrity of
the data and the accuracy of the data and the accuracy of the analysis.
Design and conduct of the study: Kereiakes, Yeh, Massaro, Mauri
Collection, management, analysis and interpretation of the data: Kereiakes, Yeh, Massaro, Mauri, Driscoll-Shempp
Preparation, review, or approval of the manuscript: Kereiakes, Yeh, Massaro, Mauri
Decision to submit the manuscript for publication: Kereiakes, Yeh, Mauri
Previous Presentation: Results were presented in an abstract and in a presentation at the American Heart Association Scientific
Sessions; Chicago, IL, November 18, 2014.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of
Interest. Dr. Kereiakes reports no conflicts of interest. No other disclosures were reported.

Kereiakes et al.

Page 2

Author Manuscript

Objective—To compare: (1) rates of stent thrombosis and major adverse cardiac and
cerebrovascular events (MACCE; composite of death, myocardial infarction, or stroke) after 30
vs. 12 months of thienopyridine in patients treated with BMS taking aspirin; and (2) treatment
duration effect within the combined cohorts of randomized DES or BMS-treated patients as
prespecified, secondary analyses of the Dual Antiplatelet Therapy Study.
Design, Setting, Participants—International, multicenter, randomized, double-blinded,
placebo-controlled trial, comparing extended (30 months) thienopyridine versus placebo in
aspirin-treated patients who completed 12 months of DAPT without bleeding or ischemic events
post-stenting. Study initiation August 2009 with last follow-up visit May 2014.
Exposure/Intervention—Continued thienopyridine or placebo at months 12-30 after stenting,
in 11648 randomized patients treated with aspirin, of whom 1687 received BMS and 9961 DES.
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Main Outcome and Measures—Stent thrombosis, MACCE, moderate/severe bleeding.
Results—Among 1687 BMS-treated patients randomized to continued thienopyridine vs.
placebo, rates of stent thrombosis were 0.5% vs. 1.11%, (N=4 vs. 9, hazard ratio 0.49, 95% CI
0.15-1.64, P=0.24), MACCE 4.04% vs. 4.69%, (N=33 vs. 38, hazard ratio 0.92, 95% CI 0.57-1.47,
P=0.72) and moderate/severe bleeding 2.03% vs. 0.90% (N=16 vs. 7, P=0.07), respectively.
Among all 11,648 randomized patients (both BMS- and DES-treated), stent thrombosis rates were
0.41% vs. 1.32%, (N=23 vs. 74, hazard ratio 0.31, 95% CI 0.19-0.50, P<0.001), MACCE 4.29%
vs. 5.74% (N=244 vs. 323, hazard ratio 0.73, 95% CI 0.62-0.87, P<0.001), and moderate/severe
bleeding 2.45% vs. 1.47% (N=135 vs. 80, P<0.001).
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Conclusions and Relevance—Among patients undergoing coronary stenting with BMS and
who tolerated 12 months of thienopyridine, continuing thienopyridine for an additional 18 months
compared with placebo did not result in statistically significant differences in rates of stent
thrombosis, MACCE, or moderate/severe bleeding. However, the BMS subset may have been
underpowered to identify such differences and further trials are suggested. (DAPT
ClinicalTrials.gov number NCT00977938).

Introduction
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While current clinical practice guidelines recommend a minimum of only 1 month of dual
antiplatelet therapy (DAPT) after bare metal stent (BMS) placement following elective
percutaneous coronary intervention (PCI; compared with 6-12 months for drug-eluting
stents [DES]),1,2 patients with acute coronary syndromes (ACS) benefit from 12 months of
therapy whether or not PCI with stenting is performed.3 Although randomized trial results
(the Dual Antiplatelet Therapy Study)4 showed a reduction in stent thrombosis and non-stent
related myocardial infarction (MI) with thienopyridine therapy beyond 12 months following
DES (among patients tolerating DAPT to 12 months), few trials have assessed optimal
duration of DAPT following BMS.5 Because BMS remain a commonly used alternative
treatment strategy to DES, particularly for patients who present with ACS or in whom
DAPT has perceived increased bleeding risk,6,7 we aimed to compare (1) rates of stent
thrombosis or major adverse cardiovascular and cerebrovascular events (MACCE) in
randomized BMS-treated patients and (2) treatment duration effect among all randomized
patients in the Dual Antiplatelet Therapy Study.
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Methods
Study Objectives and Hypotheses
We compared the randomized treatment effect of continued thienopyridine vs. placebo
beyond 12 months with regard to stent thrombosis, MACCE, and bleeding after
randomization until the completion of study drug treatment at 30 months among BMStreated patients as well as the combined BMS- and DES-treated cohort. As a post hoc
analysis, we assessed the consistency of treatment duration effect between patients treated
with BMS or DES.
Study Design

Author Manuscript

The DAPT Study design has previously been described.8 This double-blind, international,
randomized clinical trial compared the risks and benefits of continued thienopyridine
(clopidogrel or prasugrel) versus placebo, when given in addition to aspirin for the
prevention of stent thrombosis or MACCE following coronary stenting with either DES or
BMS in patients who tolerated DAPT to 12 months (ClinicalTrials.gov # NCT00977938).
The results comparing randomized treatments in the DES-treated cohort have been reported
separately.4
All institutions received approval from their Institutional Review Boards and each patient
provided written informed consent for study participation.
Study Population and Procedures
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In brief, patients who were candidates for DAPT and who received treatment with either
DES or BMS were recruited. Stent treatment was performed according to site standards of
care using only Food and Drug Administration-approved DES and BMS devices. DES types
included Cypher sirolimus-eluting stent (Cordis, Warren, NJ), Endeavor zotarolimus-eluting
stent (Medtronic, Santa Rosa, CA), TAXUS paclitaxel-eluting stent (Boston Scientific,
Marlborough, MA), and Xience/Promus everolimus-eluting stents (Abbott Vascular, Santa
Clara, CA or Boston Scientific, Marlborough, MA). All patients >18 years of age who met
all enrollment inclusion and none of the exclusion criteria (Appendix Table 2), and signed
the consent and were enrolled into the trial within 3 days of the index procedure and all
received open-label aspirin plus thienopyridine for the first 12 months. As required by
regulatory authorities, race and ethnicity data were collected via patient self-report. Race
categories for this study were pre-specified as America Indian or Alaska Native, Asian,
Black or African American, Native Hawaiian or Other Pacific Islander, White and Other,
specify. Ethnicity was collected as Hispanic or Latino and Not Hispanic or Latino. At 12
months, patients who were alive and free from MI, stroke, repeat coronary revascularization,
stent thrombosis, and moderate or severe bleeding and who demonstrated compliance with
thienopyridine treatment were then eligible for randomization (Figure 1) to continued
thienopyridine or placebo, and all continued aspirin. A computer-generated randomization
schedule stratified patients according to the type of stent they had received (drug eluting vs.
bare metal), hospital site, thienopyridine type, and presence or absence of at least one
prespecified clinical- or lesion-related risk factor for stent thrombosis (see Appendix Table
1).
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Post-randomization study procedures and follow-up were the same for BMS- and DEStreated patients.
Study Endpoints
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The co-primary effectiveness end points were cumulative incidence of definite/probable
stent thrombosis according to the Academic Research Consortium classification9 and
incidence of MACCE at 12-30 months. For randomized comparison of DAPT duration
among BMS-treated patients, the primary safety endpoint was moderate or severe bleeding
(Global Utilization of Streptokinase and TPA for Occluded Arteries [GUSTO]
classification)10 at 12-30 months. Finally, clinically actionable non-coronary artery bypass
graft related bleeding was also evaluated according to the Bleeding Academic Research
Consortium definitions (BARC 2, 3 or 5 classes).11 These events were adjudicated by an
independent Clinical Events Committee blinded to treatment assignment and administered
by HCRI. An unblinded independent central data monitoring committee oversaw the safety
of all patients.
Statistical Analysis

Author Manuscript

Among patients treated with BMS and randomized to continued thienopyridine vs. placebo,
the cumulative incidence of stent thrombosis and of MACCE are presented according to
intention-to-treat. Treatments were compared using a log-rank test stratified by geographic
region (North America, Europe, and Australia/New Zealand), thienopyridine type, and
presence/absence of stent thrombosis risk factors (listed in Table 1).8 For each endpoint, the
stratified hazard ratio (HR) and its 2-sided 95% CI comparing continued thienopyridine vs.
placebo are presented. Patients not experiencing the co-primary endpoints 12-30 months
post-index procedure were censored at the time of last known contact or 30 months,
whichever was earlier.
The analysis of the BMS cohort comparing randomized treatment arms was a prespecified
secondary analysis of the DAPT Study that was not powered to compare treatment arms
within this cohort (the powered DES-treated cohort has been previously presented4) but was
performed to assess consistency of the randomized treatment effect in BMS- vs. DES-treated
patients from the Dual Antiplatelet Therapy Study. Stent-type-by-randomized treatment
interaction was assessed using Cox proportional hazards regression as a post hoc analysis,
and the stratified HR, 95% CI, and P values for interaction are presented. All other analyses
presented were prespecified.
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All statistical analyses were conducted at HCRI with SAS software, version 9.2. (SAS
Institute Inc., Cary, NC). All p-values are two-sided and considered significant at the 0.05
level.

Results
Study Population
Enrollment in the Dual Antiplatelet Therapy Study was conducted between August
2009 and July 2011, with the last follow-up visit conducted in May 2014. Of 2816 enrolled

JAMA. Author manuscript; available in PMC 2015 June 26.

Kereiakes et al.

Page 5

Author Manuscript

BMS-treated patients, 583 (20.7%) were not eligible for randomization after 12 months of
follow-up, 546 (19.4%) were eligible but not randomized, and 1687 (59.9%) were
randomized (Figure 1). Of 25682 total enrolled patients, 5844 (22.8%) were not eligible for
randomization after 12 months of follow-up, 8190 (31.9%) were eligible but not
randomized, and 11648 (45.4%) were randomized, with median follow up of 990 days (25%
Q1: 981 days; 75% Q2: 990 days) (Appendix Figure 1). The most common reason for nonrandomization was withdrawal of patient consent.
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Baseline characteristics of BMS-treated randomized patients were similar between the
groups (Table 1). While the same inclusion and exclusion criteria were applied to all
enrolled patients, DES- and BMS-treated patients differed according to clinical and
procedural characteristics (Appendix Table 1). DES-treated patients were more likely to
have a history of diabetes mellitus (30.6% vs. 21.2%, P<0.001), hypertension, previous PCI,
and to have longer lesions, with smaller reference vessel diameter, while BMS-treated
patients were more likely to present with ST-elevation MI (STEMI, 37.6% vs. 10.5%,
P<0.001), or non-STEMI (20.9% vs. 15.5%, P<0.001), and were more likely to have
thrombus noted in the treated lesion. The baseline characteristics of the randomized, DEStreated patients have been previously published.4 Baseline characteristics of all randomized
patients were similar between the randomly assigned treatment groups (Appendix Table 1).
Predefined risk factors for stent thrombosis were present in 54% of patients in each
randomly assigned treatment group.
Effect of Continued Thienopyridine Therapy Among BMS–Treated Patients

Author Manuscript

Within randomized BMS-treated patients, the cumulative incidence of stent thrombosis and
MACCE were 0.5% vs. 1.1% (HR 0.49, 95% CI 0.15-1.64, log-rank P=0.24) and 4.0% vs.
4.7% (HR 0.92, 95% CI 0.57-1.47, log-rank P=0.72), respectively, for continued
thienopyridine vs. placebo at 12-30 months after the index procedure (Table 2). GUSTO
severe/moderate bleeding events occurred in 2.03% vs. 0.90% among BMS-treated patients
randomized to continued thienopyridine vs. placebo (P=0.07); and BARC 2, 3, or 5 bleeding
events occurred in 4.56% vs. 1.80% respectively (P=0.002). Severe bleeding was
uncommon and fatal bleeding events (BARC 5) were rare and not different between
treatment groups (Table 2).
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The results comparing continued thienopyridine vs. placebo in the DES-treated cohort have
been reported previously and demonstrated significant reductions in study co-primary
endpoints of stent thrombosis (0.4% vs. 1.4%, respectively, HR 0.29, 95% CI 0.17-0.48) and
MACCE (2.0% vs. 1.5%, respectively, HR 0.71, 95% CI 0.59-0.85) (driven by a reduction
in both stent and non-stent related MI, Table 3). An increase in moderate/severe bleeding
events was observed (2.5% vs. 1.6%, respectively, P=0.001), and a difference in all-cause
mortality rate that was not statistically significant was seen 2.0% vs. 1.5% (p=0.052), yet
mortality was infrequently related to bleeding (0.1% vs. 0.1% fatal bleeding, P=0.38, and
0.22% vs. 0.06% bleeding-related mortality, p=0.57).1
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Consistency of Effects of Continued Thienopyridine Across BMS- and DES-Treated
Patients
The post hoc analysis of the effect of continued thienopyridine found non-significant
interactions between randomized BMS- and DES-treated patients for both stent thrombosis
(interaction P=0.42) and MACCE (interaction P=0.32, Table 3).
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Among all randomized patients, the co-primary effectiveness endpoints of stent thrombosis
(0.41% vs. 1.32%; HR 0.31, 95% CI 0.19-0.50; P<0.001) and MACCE (4.29% vs. 5.74%;
HR 0.73, 95% CI 0.62-0.87; P<0.001) were reduced by continued thienopyridine versus
placebo, respectively (Table 4). The reduction in stent thrombosis was largely explained by
a reduction in definite stent thrombosis and the reduction in MACCE was largely explained
by a 48% relative reduction (1.83% absolute) in MI. Significant reductions in MI related to
stent thrombosis (0.38% vs. 1.28%, HR 0.29, 95% CI 0.18-0.48; P<0.001) as well as MI not
related to stent thrombosis (1.84% vs. 2.75%, HR 0.65, 95% CI 0.50-0.84; P<0.001) were
observed. In contrast, there is an increased incidence of severe/moderate bleeding events
(2.45% vs. 1.47%, risk difference 0.98, 95% CI 0.46-1.50; P<0.001) largely explained by
the relative increase in moderate bleeding (1.65% vs. 0.96%, risk difference 0.70, 95% CI
0.27-1.12; P=0.001). Similarly, although BARC Types 2, 3, or 5 bleeding events were
significantly increased in the continued thienopyridine treatment group (5.44% vs. 2.78%,
HR 2.65, 95% CI 1.91-3.40; P<0.001), fatal (Type 5) BARC bleeding events were rare and
not different between groups (0.13% vs. 0.09%, HR 0.04, 95% CI -0.09 to 0.16; p=0.58;
Table 4).

Discussion
Author Manuscript
Author Manuscript

Among patients undergoing coronary stenting with BMS and who tolerated 12 months of
thienopyridine, continuing thienopyridine for an additional 18 months compared to placebo
did not result in statistically significant differences in rates of stent thrombosis, MACCE, or
moderate/severe bleeding. However, limitations in sample size and power make definitive
conclusions regarding DAPT treatment duration effects difficult. While fewer BMS-treated
patients were enrolled and randomized because of the prevailing use of DES in clinical
practice, among patients eligible for continued DAPT, in a post hoc analysis we found nonsignificant interactions for the effect of continued thienopyridine therapy on stent
thrombosis among BMS- and DES-treated patients who were randomized in the Dual
Antiplatelet Therapy Study.4 However, as this comparison of treatment interaction was not
adequately powered for definitive interpretations, true differences in treatment effect size
may not have been detected and the observation that continued thienopyridine therapy
beyond one year (in patients who tolerated DAPT for one year without major bleeding) may
prevent ischemic events independent of stent type (DES or BMS) should be considered
hypothesis-generating.
Indeed, BMS-treated patients accrue target lesion (stent) related events in ≥2% per year12
and non-target lesion/vessel events in ≥5% per year following stent deployment.13,14 Late
atherothrombotic events following BMS may be due to lack of healing/uncovered stent
struts, neoatherosclerosis,15 restenosis,16 or disease progression outside the stent, in other
regions or vessels. The largest portion of MI prevented by extended duration thienopyridine
JAMA. Author manuscript; available in PMC 2015 June 26.
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therapy in this study did not involve the stented coronary segments for either DES or BMS.
While bleeding events were similarly increased with continued thienopyridine therapy
beyond one year in both BMS and DES treated patients, these events were infrequently
severe and rarely fatal (BARC 5 classification).11 The numeric increase in mortality
associated with continued thienopyridine therapy (2.0 vs. 1.5%, p=0.052) that was observed
in the DES-treated cohort, was not evident among BMS-treated randomized patients (1.0%
vs. 1.2%, P=0.83).
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The lack of apparent treatment interaction between DES and BMS supports the combined
analysis of treatment effects of continued duration of therapy independent of stent type.
Among the combined BMS and DES cohort, the reductions in stent thrombosis and MACCE
were 69% and 27%, respectively in patients continuing thienopyridine therapy together with
aspirin. 50% of the MIs prevented by continued DAPT were not stent thrombosis related.
These ischemic event benefits were balanced by a 67% relative increase in moderate
bleeding

Limitations
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The major limitation of the BMS randomized comparison of DAPT duration is sample size
and lack of power which limits the interpretability of the findings. However, an adequately
powered randomized BMS cohort would require approximately 8,000 additional patients,
which was practically not feasible under financial and logistic constraints of the study. An
adequate number of BMS-treated patients were enrolled to allow a powered comparison of
stent thrombosis and MACCE rates with patients treated with DES,17 the results of which
have been presented separately.18 In this context, the design of the BMS randomized
comparison was to evaluate for consistency or heterogeneity compared with the DES
treatment effect in an exploratory fashion, rather than to be powered for a separate,
independent analysis. Nonetheless, the BMS cohort sample size exceeds that of prior
randomized BMS cohorts evaluating duration of antiplatelet therapy5 and is similar in size
to many prior randomized trials of DAPT duration in DES.5,19-22 While similar inclusion
criteria were required of BMS- and DES-treated patients, there were systematic differences
between BMS- and DES-treated patients with a higher frequency of MI presentation prior to
the index PCI procedure for BMS and a higher prevalence of restenosis risk factors for DEStreated patients. Nevertheless, each cohort was balanced across randomized treatment arms
as expected according to the stratified randomization.

Conclusions
Author Manuscript

Among patients undergoing coronary stenting with BMS and who tolerate 12 months of
thienopyridine and aspirin therapy without major bleeding, continuing thienopyridine
therapy in addition to aspirin beyond 12 months, did not result in statistically significant
differences in rates of stent thrombosis, MACCE or moderate/severe bleeding. However, the
BMS subset may have been underpowered to determine such differences.
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JAMA. Author manuscript; available in PMC 2015 June 26.

Kereiakes et al.

Page 8

Author Manuscript

Acknowledgments
Sponsored by Harvard Clinical Research Institute. Funded by Abbott, Boston Scientific Corporation, Cordis
Corporation, Medtronic, Inc., Bristol-Myers Squibb Company/Sanofi Pharmaceuticals Partnership, Eli Lilly and
Company, and Daiichi Sankyo Company Limited and the US Department of Health and Human Services
(1RO1FD003870-01).
Additional Contributions: We thank the other investigators, the staff, and the participants of the DAPT Study for
their valuable contributions. We wish to acknowledge Joanna Suomi, MSc, for assistance editing and formatting
this manuscript, Wen-Hua Hsieh, PhD, for assistance with statistical analysis. Both Ms. Suomi and Ms. Hsieh are
employed by Harvard Clinical Research Institute and were compensated for their contributions to this manuscript.
Funding: This research has been sponsored by Harvard Clinical Research Institute and funded by Abbott, Boston
Scientific Corporation, Cordis Corporation, Medtronic, Inc., Bristol-Myers Squibb Company/Sanofi
Pharmaceuticals Partnership, Eli Lilly and Company, and Daiichi Sankyo Company Limited and the US
Department of Health and Human Services (1RO1FD003870-01).

Author Manuscript

Role of the Sponsors: The funding manufacturers and FDA had input on the study design and conduct of the study.
HCRI oversaw the collection, management, and analysis of the data; the study authors were responsible for
interpretation of the data, preparation of the manuscript, and the decision to submit the manuscript for publication.

Author Manuscript
Author Manuscript

Dr. Yeh reports personal fees from Abbott Vascular, personal fees and non-financial support from Harvard Clinical
Research Institute, during the conduct of the study; personal fees from Gilead Sciences, outside the submitted work.
Dr. Massaro reports personal fees from Harvard Clinical Research Institute during the conduct of the study. Ms.
Driscoll-Shempp has nothing to disclose. Dr. Cutlip reports other from Medtronic, other from Boston Scientific,
other from Cordis Inc., other from Abbott Vascular, grants from NHLBI, during the conduct of the study Dr. Steg
reports personal fees from Amarin, personal fees from Bayer, personal fees from Boehringer-Ingelheim, personal
fees from Bristol-Myers-Squibb, personal fees from Daiichi-Sankyo, personal fees from GlaxoSmithKline, personal
fees from Lilly, personal fees from Merck-Sharpe-Dohme, personal fees from Novartis, personal fees from Otsuka,
personal fees from Pfizer, personal fees from Roche, personal fees from Medtronic, grants and personal fees from
Sanofi, grants and personal fees from Servier, personal fees from Vivus, personal fees from The Medicines
Company, personal fees from Orexigen, outside the submitted work. Dr. Gershlick reports personal fees from
Medtronic, personal fees from Abbott, grants from Medicines Company, during the conduct of the study. Dr.
Darius reports grants from Harvard Clinical Research Institute, during the conduct of the study. Dr. Meredith
reports other from Boston Scientific, other from Medtronic, outside the submitted work. Dr. Ormiston has nothing
to disclose. Dr. Tanguay reports personal fees and other from Abbott Vascular, personal fees and other from
AstraZeneca, personal fees from Bayer, personal fees and other from Bristol-Myers Squibb, personal fees and other
from Eli Lilly, personal fees and other from GlaxoSmithKline, personal fees from Roche, personal fees and other
from Sanofi-Aventis, personal fees from Servier, other from Ikaria, other from Merck, during the conduct of the
study. Dr. Windecker reports grants from St Jude Medical, grants from Biotronik, grants from Medicines Company,
grants from Abbott, grants from Medtronic, grants from Edwards Lifesciences, personal fees from Astra Zeneca,
personal fees from Eli Lilly, personal fees from Abbott, personal fees from Biosensors, personal fees from
Biotronik, personal fees from Bayer, outside the submitted work. Dr. Garratt reports grants from Boston Scientific
Corporation, personal fees from Boston Scientific Corporation, personal fees from The Medicines Company, grants
from Abbott Vascular, personal fees from Abbott Vascular, grants from CeloNova, other from Infarct Reduction
Technologies, Inc, other from Guided Delivery Systems, personal fees from Daiichi-Sankyo/Lilly, outside the
submitted work. Dr. Kandzari reports grants from Medtronic CardioVascular, grants from Abbott Vascular, grants
from Boston Scientific, grants from Biotronik, personal fees from Micell Technologies, personal fees from
Medtronic CardioVascular, personal fees from Boston Scientific, outside the submitted work. Dr. Lee reports grants
from Boston Scientific, during the conduct of the study; personal fees from Boston Scientific, personal fees from
Medtronic, outside the submitted work. Dr. Simon reports other from Cordis/Johnson & Johnson, during the
conduct of the study; personal fees from Cordis/Johnson & Johnson, personal fees from Medtronic Vascular,
outside the submitted work. Dr. Iancu has nothing to disclose. Dr. Tr ębacz has nothing to disclose. Dr. Mauri
reports grants from Abbott, grants from Boston Scientific, grants from Medtronic, grants from Cordis, grants from
Eli Lilly, grants from Daiichi Sankyo, grants from Bristol Myers Squibb, grants from Sanofi-Aventis, during the
conduct of the study; personal fees from Medtronic, personal fees from St Jude, grants and personal fees from
Biotronik, outside the submitted work.

References
1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous
Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and
Interventions. Circulation. 2011; 124:e574–651. [PubMed: 22064601]

JAMA. Author manuscript; available in PMC 2015 June 26.

Kereiakes et al.

Page 9

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

2. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial
revascularization: The Task Force on Myocardial Revascularization of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed
with the special contribution of the European Association of Percutaneous Cardiovascular
Interventions (EAPCI). Eur Heart J. 2014; 35:2541–619. [PubMed: 25173339]
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition
to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med.
2001; 345:494–502. [PubMed: 11519503]
4. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after
Drug-Eluting Stents. N Engl J Med. 2014; 371(23):2155–66. [PubMed: 25399658]
5. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet
therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125:2015–26.
[PubMed: 22438530]
6. Badheka A, Arora S, Panaich S, et al. Impact on In-Hospital Outcomes With Drug-Eluting Stents
Versus Bare-Metal Stents (from 665,804 Procedures). Am J Cardiol. 2014 Dec 1; 114(11):1629–37.
[PubMed: 25439448]
7. Douglas PS, Brennan JM, Anstrom KJ, et al. Clinical effectiveness of coronary stents in elderly
persons: results from 262,700 Medicare patients in the American College of Cardiology-National
Cardiovascular Data Registry. J Am Coll Cardiol. 2009; 53:1629–41. [PubMed: 19406337]
8. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy
study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and
safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous
coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment
of coronary artery lesions. Am Heart J. 2010; 160:1035–41. 41 e1. [PubMed: 21146655]
9. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for
standardized definitions. Circulation. 2007; 115:2344–51. [PubMed: 17470709]
10. An international randomized trial comparing four thrombolytic strategies for acute myocardial
infarction. The GUSTO investigators. N Engl J Med. 1993; 329:673–82. [PubMed: 8204123]
11. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical
trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;
123:2736–47. [PubMed: 21670242]
12. Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 20 years) clinical and angiographic
outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv. 2010; 3:468–75.
[PubMed: 20823392]
13. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from
second-generation coronary stent trials. Circulation. 2004; 110:1226–30. [PubMed: 15337693]
14. Chacko R, Mulhearn M, Novack V, et al. Impact of target lesion and nontarget lesion cardiac
events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. JACC
Cardiovasc Interv. 2009; 2:498–503. [PubMed: 19539252]
15. Takano M, Yamamoto M, Mizuno K. Two cases of coronary stent thrombosis very late after baremetal stenting. JACC Cardiovasc Interv. 2009; 2:1286–7. [PubMed: 20129558]
16. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a
benign clinical entity. Am Heart J. 2006; 151:1260–4. [PubMed: 16781233]
17. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in
randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356:1020–9. [PubMed:
17296821]
18. Kereiakes DJ, Yeh RW, Massaro JM, et al. Comparison of ischemic events after drug-eluting
stents or bare metal stents in subjects receiving dual antiplatelet therapy: results from the
randomized Dual Antiplatelet Therapy Study. Circulation. 2014; 130(23):2113. Abstract.
19. Gilard M, Barragan P, Noryani AA, et al. Six-month versus 24-month dual antiplatelet therapy
after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized
multicenter trial. J Am Coll Cardiol. 2014 Nov 16. Epub ahead of print.
20. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after
implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late

JAMA. Author manuscript; available in PMC 2015 June 26.

Kereiakes et al.

Page 10

Author Manuscript

Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012; 125:505–
13. [PubMed: 22179532]
21. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after
zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310:2510–22.
[PubMed: 24177257]
22. Colombo A, Chieffo A, Frasheri A, et al. Second Generation Drug-Eluting Stents Implantation
Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy- The SECURITY
Randomized Clinical Trial. J Am Coll Cardiol. 2014; 64(20):2086–99. [PubMed: 25236346]
23. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of
procedural outcome with angioplasty for multivessel coronary disease. Implications for patient
selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990; 82:1193–202.
[PubMed: 2401060]

Author Manuscript
Author Manuscript
Author Manuscript
JAMA. Author manuscript; available in PMC 2015 June 26.

Kereiakes et al.

Page 11

Author Manuscript
Author Manuscript
Author Manuscript

Figure 1.

Enrollment, Randomization, and Follow-up Among Randomized Bare Metal Stent-Treated
Patients.
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Table 1

Author Manuscript

Baseline Characteristics of Randomized Bare Metal Stent-Treated Patients.*
Characteristics

Continued Thienopyridine
N=842

Placebo
N=845

% (N) reported for non-continuous variable
Patients
Age (years), mean ±SD

Author Manuscript

58.9 ±10.5

59.2 ±11.1

25.5% (215)

21.8% (184)

Race- non-White**

7.5% (62)

7.3% (61)

Weight (kg), mean ±SD

88.0 ±18.4

88.5 ±18.8

BMI(Kg/m2),

29.5 ±5.2

29.6 ±5.6

Diabetes mellitus

21.7% (181)

20.7% (173)

Hypertension

64.0% (534)

64.6% (543)

Cigarette smoker

43.3% (360)

43.3% (350)

Stroke/TIA

5.1% (43)

4.0% (34)

Congestive heart failure

4.2% (35)

3.3% (28)

Female

mean ±SD

Peripheral arterial disease
Prior PCI
Prior CABG
Prior MI
Indication for PCI

4.2% (35)

5.5% (46)

17.9% (150)

20.3% (171)

6.0% (50)

5.9% (50)

19.4% (160)

21.5% (178)

58.8%

58.3%

58.8% (495)

58.3% (493)

STEMI

36.9% (311)

38.3% (324)

NSTEMI

21.9% (184)

20.0% (169)

9.1% (77)

9.6% (81)

23.6% (199)

23.4% (198)

8.4% (71)

8.6% (73)

69.2% (568)

69.0% (569)

64.0% (525)

63.2% (521)

58.8% (495)

58.3% (493)

3.4% (28)

2.4% (20)

ACS

Author Manuscript

Unstable Angina***
Stable Angina
Other
Any risk factor for stent thrombosis
Any Clinical
Enzyme positive ACS (STEMI or NSTEMI)
Renal insufficiency/failure
LVEF < 30%

4.0% (32)

3.6% (29)

38.7% (325)

37.5% (316)

> 2 vessels stented

0.0% (0)

0.1% (1)

> 2 lesions per vessel

1.1% (9)

1.0% (8)

Lesion length ≥ 30 mm

6.5% (55)

6.6% (56)

Bifurcation lesion sidebranch ≥ 2.5 mm

4.5% (38)

4.0% (34)

Any Lesion-Related

Author Manuscript

In-stent restenosis of a DES

0.4% (3)

0.7% (6)

Vein bypass graft stented

2.6% (22)

2.4% (20)

Unprotected left main stented

0.0% (0)

0.1% (1)

Thrombus-containing lesion

28.9% (243)

25.9% (219)

0.1% (1)

0.1% (1)

Prior Brachytherapy
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Characteristics

Continued Thienopyridine
N=842

Placebo
N=845

Author Manuscript

% (N) reported for non-continuous variable
Region
North America

60.5% (509)

61.4% (519)

Europe

36.1% (304)

35.5% (300)

3.4% (29)

3.1% (26)

Clopidogrel

86.7% (730)

86.6% (732)

Prasugrel

13.3% (112)

13.4% (113)

Number of treated lesions, mean ±SD

1.2 ±0.4

1.12 ±0.4

Number of treated vessels, mean ±SD

1.0 ±0.2

1.1 ±0.2

Number of stents, mean ±SD

1.3 ±0.6

1.3 ±0.6

<3

23.9% (201)

24.4% (206)

≥3

76.1% (641)

75.6% (639)

24.0 ±13.0

23.9 ±13.1

Australia or New Zealand
Thienopyridine drug at randomization

Minimum stent diameter (per subject)

Author Manuscript

Total stent length (mm), mean ±SD
Lesions†
Treated Vessel
Left main

0.0% (0)

0.1% (1)

LAD

31.6% (308)

30.9% (306)

Right

44.8% (437)

45.6% (452)

Circumflex

21.1% (206)

20.9% (207)

Venous graft

2.5% (24)

2.5% (25)

Arterial graft

0.0% (0)

0.0% (0)

47.6% (440)

47.8% (450)

Modified ACC/AHA lesion class B2 or C

Author Manuscript

Abbreviations: ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; BMI, body mass
index; CABG, coronary artery bypass graft; DES, drug-eluting stent; LAD, left anterior descending; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; NSTEMI, non-ST elevation MI; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI; TIA, transient ischemic
attack.
*

For all variables, 0-4% of subjects had missing values.

**

Race was self-reported.

***

This category included unstable angina without reported elevation of cardiac enzymes.

†

A total of 975 lesions were treated in the continued thienopyridine group and 991 in the placebo group.

‡

The definitions of class B2 and class C lesions according to the modified American College of Cardiology (ACC)–American Heart Association

(AHA) criteria.23
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Table 2

Ischemic and Bleeding Outcomes In Randomized Bare Metal Stent-Treated Patients

Author Manuscript

Patients were randomized to continued thienopyridine or placebo plus aspirin 12 months after receiving a bare
metal stent. The effectiveness endpoints, stent thrombosis and MACCE, are shown over the primary analysis
period, e.g. 12-30 months after enrollment. For the safety endpoint of GUSTO severe or moderate bleeding,
patients whose last contact date was ≥ 510 days post randomization or who experienced any adjudicated
bleeding outcome at or before 540 days were included.
Continued Thienopyridine
N=8421

Placebo
N=8451

Hazard Ratio
(95% CI)

Log-rank P-Value

Ischemic Outcomes

No. of patients (%)

Stent thrombosis*

4 (0.50)

9 (1.11)

0.49 (0.15, 1.64)

0.24

4 (0.50)

9 (1.11)

0.49 (0.15, 1.64)

0.24

Definite

Author Manuscript

Probable

0 (0.00)

0 (0.00)

N/A

.

33 (4.04)

38 (4.69)

0.92 (0.57, 1.47)

0.72

Death, all cause

8 (0.99)

10 (1.24)

0.90 (0.35, 2.33)

0.83

MI

22 (2.70)

25 (3.10)

0.91 (0.51, 1.62)

0.74

MACCE (death, MI, stroke)

Stent thrombosis-related

4 (0.50)

9 (1.11)

0.49 (0.15, 1.64)

0.24

Non stent thrombosis-related

18 (2.21)

16 (1.99)

1.12 (0.57, 2.20)

0.74

Stroke (total)

6 (0.73)

5 (0.62)

1.22 (0.37, 4.01)

0.74

Ischemic

4 (0.49)

5 (0.62)

0.82 (0.22, 3.05)

0.77

Hemorrhagic

1 (0.12)

0 (0.00)

N/A

0.32

Type Uncertain

1 (0.12)

0 (0.00)

N/A

0.32

Bleeding Complications**

Continued Thienopyridine
N=790

Placebo
N=776

Author Manuscript

No. of patients (%)
GUSTO Severe/Moderate

Risk Difference

2-Sided P Value for Difference

Percentage points (95% CI)

16 (2.03)

7 (0.90)

1.12% (-0.06%,2.31%)

0.07

GUSTO Severe

6 (0.76)

3 (0.39)

0.37% (-0.37%,1.12%)

0.33

GUSTO Moderate

10 (1.27)

4 (0.52)

0.75%(-0.18%,1.68%)

0.12

BARC Types 2, 3, or 5

36 (4.56)

14 (1.80)

2.75% (1.02%,4.48%)

0.002

BARC Type 2

22 (2.78)

7 (0.90)

1.88% (0.56%,3.21%)

0.01

BARC Type 3

16 (2.03)

6 (0.77)

1.25% (0.09%,2.41%)

0.04

BARC Type 5

0 (0.00)

1 (0.13)

-0.13% (-0.38%,0.12%)

0.31

Abbreviations: ARC, Academic Research Consortium; BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of
Streptokinase and TPA for Occluded Arteries; MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction.
Please see Supplementary Appendix: Table 3 for GUSTO and BARC definitions.
*

Author Manuscript

Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.

**

The primary safety end point was moderate or severe bleeding as assessed according to GUSTO criteria. Only patients who could be evaluated
were included in this analysis (i.e., patients whose last contact date was ≥510 days after randomization or who had any adjudicated bleeding event
at or before 540 days). Patients could have had more than one bleeding episode. The secondary analysis of bleeding is assessed according to the
criteria of the BARC criteria.
1

Percentages are Kaplan-Meier estimates.
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Table 3

Treatment Interaction by Stent Type on Outcomes

Author Manuscript

Analyses of treatment interaction by stent type, shown with Kaplan-Meier event rates, hazard ratios and 95%
confidence intervals (CI) for efficacy and safety outcomes at 12-30 months among all randomized patients
(9961 drug-eluting stent-treated and 1687 bare metal stent-treated).
Continued Thienopyridine
N (%)

Placebo
N (%)

Hazard Ratio
(95% CI)

P Value for Interaction

No. of patients (%)
Definite or Probable Stent Thrombosis*

0.42

DES

19 (0.4)

65 (1.4)

0.29 (0.17,0.48)

BMS

4 (0.5)

9 (1.1)

0.49 (0.15,1.64)

DES

211 (4.3)

285 (5.9)

0.71 (0.59,0.85)

BMS

33 (4.0)

38 (4.7)

0.92 (0.57,1.47)

0.32

MACCE

Author Manuscript

0.41

Death
DES

98 (2.0)

74 (1.5)

1.36 (1.00,1.85)

BMS

8 (1.0)

10 (1.2)

0.90 (0.35,2.33)

DES

119 (2.5)

73 (1.5)

1.60 (1.19,2.17)

BMS

16 (1.9)

7 (0.9)

2.74 (1.05,7.00)

0.30

GUSTO Severe/Moderate Bleeding

0.04

Myocardial Infarction
DES

99 (2.1)

198 (4.1)

0.47 (0.37,0.61)

BMS

22 (2.7)

25 (3.1)

0.91 (0.51,1.62)

Abbreviations: BMS, bare metal stents; DES, drug-eluting stents; GUSTO, Global Utilization of Streptokinase and TPA for Occluded Arteries;
MACCE, major adverse cardiovascular and cerebrovascular events.

Author Manuscript

*

Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.
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Table 4

Author Manuscript

Ischemic and Bleeding Outcomes in All (Bare Metal and Drug-eluting Stent-Treated) Randomized Patients
Comparing Continued Thienopyridine vs Placebo.
Continued Thienopyridine
N=58621

Outcome

Placebo
N=57861

Hazard Ratio
(95% CI)

Log-rank P-Value

No. of patients (%)
Stent thrombosis*
Definite
Probable
MACCE (Death, MI, Stroke)

23 (0.41)

74 (1.32)

0.31 (0.19, 0.50)

<.001

19 (0.34)

67 (1.20)

0.28 (0.17, 0.47)

<.001

5 (0.09)

7 (0.12)

0.71 (0.23, 2.24)

0.56

244 (4.29)

323 (5.74)

0.73 (0.62, 0.87)

<.001

Death, all cause

106 (1.87)

84 (1.50)

1.31 (0.97, 1.75)

0.07

MI

121 (2.15)

223 (3.98)

0.52 (0.42, 0.65)

<.001

Author Manuscript

Stent thrombosis-related

21 (0.38)

72 (1.28)

0.29 (0.18, 0.48)

<.001

Non stent thrombosis-related

104 (1.84)

154 (2.75)

0.65 (0.50, 0.84)

<.001

Stroke (total)

43 (0.76)

48 (0.86)

0.84 (0.55, 1.28)

0.42

Ischemic

28 (0.50)

39 (0.70)

0.70 (0.43, 1.15)

0.16

Hemorrhagic

14 (0.25)

9 (0.16)

1.31 (0.55, 3.12)

0.53

Type uncertain

1 (0.02)

1 (0.02)

1.01 (0.06, 16.09)

1.00

Bleeding Complications**

Continued Thienopyridine
N=5500

Placebo
N=5425

No. of patients (%)
GUSTO Severe/Moderate

Difference

Two-sided P Value for Difference

Percentage points (95% CI)

Author Manuscript

135 (2.45)

80 (1.47)

0.98 (0.46, 1.50)

<.001

GUSTO Severe

44 (0.80)

29 (0.53)

0.27 (-0.04, 0.57)

0.09

GUSTO Moderate

91 (1.65)

52 (0.96)

0.70 (0.27, 1.12)

0.001

BARC Types 2, 3, or 5

299 (5.44)

151 (2.78)

2.65 (1.91, 3.40)

<.001

BARC Type 2

167 (3.04)

79 (1.46)

1.58 (1.03, 2.13)

<.001

BARC Type 3

138 (2.51)

74 (1.36)

1.15 (0.63, 1.66)

<.001

BARC Type 5

7 (0.13)

5 (0.09)

0.04 (-0.09, 0.16)

0.58

Abbreviations: BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of Streptokinase and TPA for Occluded Arteries,
MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction.
*

Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.

1

Percentages are Kaplan-Meier estimates.

Results for MACCE and stent thrombosis are for all randomized patients; patients not experiencing the endpoint are censored at 30 months or at
last known follow-up, whichever is earlier.

Author Manuscript

**
Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥510 days after randomization or
who had any adjudicated bleeding event at or before 540 days). Patients could have had more than one bleeding episode.
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